1、会议召集人：公司董事会 2、会议方式：本次股东大会采取现场投票与网络投票相结合的方式 3、现场会议时间：2025 年 9 月 12 日（星期五）14:30 证券代码：002001 证券简称：新和成 公告编号：2025-044 浙江新和成股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要提示： 本次会议召开期间未增加、否决或变更提案的情况。 一、会议召开和出席情况 4、现场会议地点：公司总部会议室（浙江省新昌县七星街道新昌大道西路 418 号） 5、现场会议主持人：董事长胡柏藩先生 6、网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间 为：2025年9月12日上午9:15-9:25、9:30－11:30，下午13:00－15:00；通过深圳证 券交易所互联网投票系统投票的具体时间为：2025年9月12日上午9:15至下午 15:00期间的任意时间。 7、本次会议的召集、召开与表决程序符合有关法律法规和《公司章程》的 规定。 二、会议出席情况 1、会议出席的情况：参加本次现场会议及网络投票的 ...

法律意见书 浙江天册律师事务所 关于 浙江新和成股份有限公司 2025 年第二次临时股东大会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 关于浙江新和成股份有限公司 2025 年第二次临时股东大会的 法律意见书 编号：TCYJS2025H1458 号 致：浙江新和成股份有限公司 根据《中华人民共和国证券法》以下简称（"证券法"）、《中华人民共和 国公司法》（以下简称"公司法"）和中国证券监督管理委员会关于《上市公司 股东会规则》（以下简称"股东会规则"）等法律、法规和其他有关规范性文件 的要求，浙江天册律师事务所（以下简称"本所"）接受浙江新和成股份有限公 司（以下简称"新和成"或"公司"）的委托，指派本所律师参加新和成 2025 年 第二次临时股东大会，并出具本法律意见书。 本法律意见书仅供新和成 2025 年第二次临时股东大会之目的使用。本所律师 同意将本法律意见书随新和成本次股东大会其他信息披露资料一并公告。 本所律师根据《股东会规则》的要求，按照律师行业公认的业 ...

9月10日，新和成盘中下跌2.03%，截至10:29，报24.16元/股，成交1.80亿元，换手率0.24%，总市值 742.54亿元。 资金流向方面，主力资金净流出2368.61万元，特大单买入955.41万元，占比5.30%，卖出2363.93万元， 占比13.11%；大单买入3742.65万元，占比20.76%，卖出4702.74万元，占比26.09%。 资料显示，浙江新和成股份有限公司位于浙江省新昌县七星街道新昌大道西路418号，成立日期1999年4 月5日，上市日期2004年6月25日，公司主营业务涉及营养品、香精香料、高分子新材料和原料药的生产 和销售。主营业务收入构成为：营养品64.86%，香精香料18.96%，新材料9.35%，其他6.83%。 新和成所属申万行业为：基础化工-化学制品-食品及饲料添加剂。所属概念板块包括：增持回购、 MSCI中国、大盘、一带一路、基金重仓等。 截至6月30日，新和成股东户数8.07万，较上期增加3.59%；人均流通股37616股，较上期减少3.47%。 2025年1月-6月，新和成实现营业收入111.01亿元，同比增长12.76%；归母净利润36.03亿元，同 ...

格隆汇9月8日丨新和成(002001.SZ)于投资者互动平台表示，公司PPS有向碱性制氢隔膜厂商出货。 ...

Core Viewpoint - The company emphasizes its commitment to innovation-driven development and market competition, focusing on fine chemicals and achieving domestic production of key products like Vitamin E and A [2] Group 1: Company Strategy - The company relies on two core platforms: chemical and biological, to develop functional chemicals in nutrition, flavors, new materials, and raw pharmaceuticals [2] - The company adheres to the values of "innovation, people-oriented, and competitive success," and follows a development approach of "integration, serialization, and collaboration" [2] Group 2: Product Development - The company has successfully achieved the domestic production of various products, including Vitamin E, Vitamin A, PPS, and methionine, contributing to industrial transformation and upgrading [2] Group 3: Future Focus - The company plans to enhance its technological innovation, global layout, and digital intelligence to strengthen management and improve overall competitiveness [2]

Core Viewpoint - The company is actively implementing its "Bio+" strategy through the development of a range of bio-fermentation products at its Heilongjiang base, focusing on high-value and technologically advanced offerings [2] Group 1: Company Strategy - The Heilongjiang base is positioned as a center for bio-fermentation products, with a focus on vitamins such as Vitamin C, Coenzyme Q10, Vitamin B5, B12, and amino acids like serine, cysteine, and tryptophan [2] - The company emphasizes a technology-first approach in the development of new products, aiming for a series of high-value, large-scale offerings [2] - There is a strong focus on extending the existing business's industrial chain and creating synergistic effects with current operations [2] Group 2: Research and Development - The company has established a bio-fermentation research institute to foster internal and external collaboration, aiming to stay at the forefront of biotechnology [2] - The goal is to create a comprehensive "Bio+" platform that integrates technology and products deeply [2]

Group 1 - The core viewpoint of the article highlights that Xinhecheng's new materials segment achieved a revenue of 1.038 billion yuan in the first half of the year, representing a 43.75% increase compared to the same period last year, driven by both volume and price increases in PPS and the HA project [2] - The new materials segment has a broad market outlook, with significant demand growth in sectors such as new energy, semiconductors, and high-end manufacturing [2] - The company plans to advance the PPS expansion project and scale up HA production in response to market demand [2]

Core Viewpoint - The company, Xinhecheng, announced on September 5 that it is focused on the nutrition, flavor and fragrance, high polymer new materials, and active pharmaceutical ingredients sectors, emphasizing innovation-driven growth and product matrix enhancement to increase revenue scale [2] Group 1 - The company is committed to the nutrition products sector [2] - The company is involved in the flavor and fragrance business [2] - The company is developing high polymer new materials [2] Group 2 - The company is engaged in the active pharmaceutical ingredients sector [2] - The company plans to continue deepening its product matrix construction [2] - The company will have new product plans across all segments to enhance revenue [2]

Core Viewpoint - The company has successfully produced qualified products from its joint venture with Sinopec, focusing on a liquid methionine project with an annual capacity of 180,000 tons [2] Group 1: Company Developments - The company announced the establishment of a joint venture with Sinopec to create Ningbo Zhenhai Refining New and Cheng Biotechnology Co., Ltd. [2] - The liquid methionine project is currently undergoing maintenance, expected to last 3-4 weeks, with future progress dependent on market demand and trial production results [2] Group 2: Project Details - The liquid methionine project has an annual production capacity of 180,000 tons [2] - The company has successfully produced qualified products from the liquid methionine project [2]

Core Viewpoint - The company reported a robust growth in key operating metrics for the first half of 2025, driven by effective market expansion and cost management strategies [2] Financial Performance - The company achieved a revenue of 11.1 billion yuan, representing a year-on-year increase of 12.76% [2] - The net profit attributable to shareholders reached 3.603 billion yuan, marking a significant year-on-year growth of 63.46% [2] - The net profit excluding non-recurring items was 3.679 billion yuan, reflecting a year-on-year increase of 70.50% [2] Segment Performance - Revenue from the nutrition products segment grew by 7.78% year-on-year [2] - Revenue from the flavor and fragrance segment increased by 9.35% year-on-year [2] - Revenue from the new materials segment saw a substantial growth of 43.75% year-on-year [2] Strategic Initiatives - The company emphasized its proactive approach to navigating complex domestic and international environments [2] - Efforts to enhance production and sales coordination contributed to improved sales volumes across major products [2] - The company implemented multiple measures to strengthen cost and expense control, leading to growth across all segments [2]